

NOTICE

ALTERNATIVE MEDICATION AUTHORIZATION

An Act respecting prescription drug insurance (chapter A-29.01, s. 60.1)

I hereby authorize the temporary use of the following alternative medication:

| | | | | | | | |
|----------|---------------|--|--------|---|------|--|--|
| 99113936 | Sulfasalazine | | 500 mg | 1 | Tab. | | |
|----------|---------------|--|--------|---|------|--|--|

until the following medication, appearing on the *List of Medications* attached to the *Regulation respecting the List of medications covered by the basic prescription drug insurance plan*, is no longer out of stock:

| | | | | | | | |
|----------|-------------------|------------|--------|-----|------|--------|--------|
| 00598461 | pms-Sulfasalazine | Phmscience | 500 mg | 500 | Tab. | 126.65 | 0.2533 |
|----------|-------------------|------------|--------|-----|------|--------|--------|

This notice has effect retroactively from 2 December 2021.

Québec, 21 December 2021

[original signed by]

MARCO THIBAUT
President and Chief Executive Officer
Régie de l'assurance maladie du Québec

Publication of this notice on the website of the Régie de l'assurance maladie du Québec imparts authentic value to it.